Archive | May, 2013

Hot Life Science Investor Mandate 1: Family Office Seeks Service Providers for Allocation – May 30, 2013

29 May

A family office in the Central United States is currently seeking to invest in, acquire or recapitalize small- to middle-market businesses. The firm is a non-traditional private equity fund in that the managers of the fund provide all of its capital. Therefore, there are no hard fund investment periods, and they are free to hold and operate portfolio companies with a very long-term perspective if required. The firm operates on an opportunistic basis and makes allocations on a case-by-case basis. They will typically invest into the tens of millions in a potential issuer. Within the life sciences and healthcare space, the partnership seeks contract manufacturing and service provider firms; they are especially interested at this time in service providers such as CRO’s and CMO’s.

Hot Life Science Investor Mandate 2: Private Equity Investor Seeking Range of Life Science Opportunities – May 30, 2013

29 May

A private equity group that invests in the life sciences space based in the Eastern US with nearly $2 billion in AUM is currently looking for new firms for potential investments for their third fund, which targeted $650 million, and currently has $350 million in dry powder to deploy to new firms over the next year or so. The firm typically allocates $20-50 million per firm, and is currently looking for firms that are seeking growth capital. The firm is interested in medtech and biotech therapeutic and diagnostic companies. The firm is very opportunistic and will look at the full gamut of subsectors. In the biotech therapeutics and diagnostics space, the fund is most interested in firms focused on infectious diseases, cardiovascular disorders, and pediatrics. They are looking for firms that have products in phase I or II of clinical trials. The firm invests in companies based globally.

Hot Life Science Investor Mandate 3: Opportunistic Family Office Invests Generally in Life Sciences – May 30, 2013

29 May

A highly opportunistic, London-based private investor backed by a single family office LP in the life sciences space is interested in making 2-4 allocations over the coming six months. Within life sciences, the firm has no specific criteria for investment and will look at opportunities regardless of sector, indication, development phase or financing round. The firm has comfortably made allocations from seed stage financings to multi-million dollar, late-stage investments. The firm has a very long-term orientation and has the capital available to make several follow-on equity capitalizations for subsequent rounds.

%d bloggers like this: